TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.08
+0.00%Aug 18, 2026, 07:49 UTC
Empowered Funds LLC acquired a new position in Theravance Biopharma, Inc., purchasing 55,463 shares valued at approximately $900,000, representing 0.11% ownership.
Source:Aug 15, 2026, 11:59 UTC
Halper Sadeh LLC announced an investigation into Theravance Biopharma's pending acquisition by Zymeworks Inc. to determine whether shareholders are receiving a fair price and whether the board complied with securities laws and fiduciary duties.
Source:Aug 10, 2026, 12:30 UTC
Theravance Biopharma reported its second quarter 2026 financial results, with YUPELRI collaboration revenue increasing 11% year-over-year to $20.7 million and a quarter-end cash balance of $388 million with no debt.
Source:Aug 10, 2026, 12:30 UTC
Theravance Biopharma entered into a definitive agreement to be acquired by Zymeworks, expected to close in the second half of 2026.
Jun 29, 2026, 00:00 UTC
Theravance Biopharma Inc. agreed to be acquired by Zymeworks Inc. via a merger in which each Theravance ordinary share will be converted into $17.00 in cash plus one contingent value right.